Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC
Conditions
Interventions
anamorelin HCl
anamorelin HCl
+1 more
Locations
33
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Osler Medical
Melbourne, Florida, United States
Augusta Oncology Associates
Augusta, Georgia, United States
South Georgia Medical Center
Valdosta, Georgia, United States
Investigative Clinical Research of Indiana
Indianapolis, Indiana, United States
John Hopkins University
Baltimore, Maryland, United States
Start Date
March 1, 2008
Primary Completion Date
December 1, 2009
Completion Date
December 1, 2009
Last Updated
April 14, 2017
NCT06855771
NCT06758401
NCT06120140
NCT04165798
NCT06667908
NCT06875310
Lead Sponsor
Helsinn Therapeutics (U.S.), Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions